Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Global Panel Urges Rapid Reform of WHO and FCTC to Embrace Science, Transparency, and Consumer Voices
WASHINGTON, June 17, 2025 /PRNewswire/ -- The Taxpayers Protection Alliance (TPA) is…
U.S. Postal Service Releases Dog Bite National Rankings
National Dog Bite Awareness Campaign starts June 1 WASHINGTON, June 14, 2025…
New Policy Brief from the NDC Partnership Guides Countries Toward Tripling Renewable Energy
The NDC Partnership released a new policy brief today to support policymakers…
WASHINGTON FREEDOM ANNOUNCES MULTI-YEAR PARTNERSHIP WITH CLOVER
Clover joins Washington Freedom as Official Partner and Kit Sponsor to elevate…